Giuseppe Derosa^{1, 2,}, Riccardo Raddino³, Antonio Maggi⁴, Gianfranco Pasini⁵, Angela D’Angelo^{1, 6}, Pamela Maffioli^{1, 7}

The aim of this study was to compare the response to an oral fat load after three months of adsumption of Esterol Tens® compared to placebo in hypercholesterolemic and hypertensive patients. We enrolled 65 patients and randomized them to take Esterol Tens®, 1 tablet once a day, or placebo for 3 months. We evaluated blood pressure, fasting plasma glucose (FPG), lipid profile, oxidized-low density lipoprotein (Ox-LDL), high sensitivity C-reactive protein (Hs-CRP), soluble vascular cell adhesion protein-1 (sVCAM-1); soluble intercellular adhesion protein-1 (sICAM-1), soluble E-selectin (sE-selectin), myeloperoxidase (MPO). All parameters were assessed at baseline, and after 3 months. In the same visits, an oral fat load was performed. Blood pressure was reduced with nutraceutical both compared to baseline, and placebo. Total cholester, triglycerides, LDL-cholesterol, and Ox-LDL decreased only with the nutraceutical. We observed a decrease of Hs-CRP, and MPO, and an increase of nitrites/nitrates after 3 months both compared to baseline and placebo with the nutraceutical treatment. Values recorded during OFL were lower in the group treated with nutraceutical compared to placebo. The nutraceutical combination improved blood pressure and lipid profile and attenuated the answer to the OFL of lipid profile and, in the same way, improved some inflammatory markers compared to placebo.

dyslipidemia, oral fat load, nutraceutical